BioWorld4h
Medtronic’s Affera PFA snags FDA approval
Medtronic plc added a second U.S. FDA pulsed field ablation (PFA) device approval to its scorecard with the agency’s ...
medtechdive10h
Medtronic wins FDA approval for Affera mapping and ablation system
Affera combines mapping technology with a catheter capable of performing radiofrequency and pulsed field ablation.
FierceBiotech10h
FDA approves Medtronic's Affera all-in-one pulsed field ablation system
Less than a year after obtaining an FDA approval for its first foray into pulsed field ablation, Medtronic has done it again.
FDA approves Medtronic’s Affera mapping and ablation system with Sphere-9 catheter
This approval is expected to help in treatment of persistent AFib and for RF ablation of CTI dependent atrial flutter.
Medtronic’s Affera ablation system granted FDA approval
Medtronic (MDT) announced FDA approval of the Affera Mapping and Ablation System with Sphere-9 Catheter, an all-in-one, high-density mapping ...
MassDevice1d
FDA approves Medtronic’s Affera cardiac mapping and ablation system and Sphere-9 catheter
Medtronic received FDA approval for the Affera mapping and ablation system and Sphere-9 catheter, which can deliver both PFA ...
Medtronic Gets FDA Approval for Affera Technology
Medtronic said the Food and Drug Administration approved its Affera mapping and ablation system with sphere-9 catheter.
Boston Scientific lifts sales outlook, notes key approval of AFib device with Minnesota ties
The med-tech company with approximately 9,400 employees in Minnesota posted profit and sales that beat Wall Street’s ...
Boston Scientific Pauses Enrollment In Farapulse Study In Drug-Naive Patients With Irregular Heart Rhythm
Boston Scientific's AVANT GUARD trial evaluates the FARAPULSE PFA System for treating persistent atrial fibrillation, pausing ...
Boston Scientific price target raised to $97 from $93 at BTIG
BTIG raised the firm’s price target on Boston Scientific (BSX) to $97 from $93 and keeps a Buy rating on the shares. The firm notes that ...